drugset / Trial / NCT03336645

Open-label Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Children With Status Epilepticus (Convulsive) in a Healthcare Setting in Japan

NCT03336645

Phase 3 Completed 25 enrolled Shire
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the efficacy, safety and pharmacokinetics of MHOS/SHP615 administered buccally in children with status epilepticus (convulsive) in a healthcare setting.

Timeline

Start
2017-10-23
Primary completion
2019-08-19
Completion
2019-08-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Midazolam Small molecule 2.5 mg Other
Subject Midazolam Small molecule 5 mg Other
Subject Midazolam Small molecule 7.5 mg Other
Subject Midazolam Small molecule 10 mg Other